New therapeutic targets for amyotrophic lateral sclerosis

Bibliography

• Brooks BR, Miller RG, Swash M, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Dengler R, Eisen A, Electrodiagnostic criteria for diagnosis of ALS Clin Neurophysiol 2008;119:497-503
   PubMed Web of Science ®Google Scholar
• Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010;48:629-41
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364:59-62
   PubMed Web of Science ®Google Scholar
• Bowling AC, Schulz JB, Brown RH Jr, Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-5
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(Suppl 1):S3-9
   PubMed Web of Science ®Google Scholar
• Gurney ME, Pu H, Chiu AY, Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-5
   PubMed Web of Science ®Google Scholar
• Reaume AG, Elliott JL, Hoffman EK, Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996;13:43-7
   PubMed Web of Science ®Google Scholar
• Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007;(1):CD002829
   Google Scholar
• Kwiecinski H, Janik P, Jamrozik Z, The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trial. Neurol Neurochir Pol 2001;35(1 Suppl):101-6
   PubMedGoogle Scholar
• Kaufmann P, Thompson JL, Levy G, Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66:235-44
   PubMed Web of Science ®Google Scholar
• Niebroj-Dobosz I, Janik P, Kwiecinski H. Effect of riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2002;106:39-43
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Tsai G, Kuncl RW, Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Forrest V, Ince PG, CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-16
   PubMedGoogle Scholar
• Lin CL, Bristol LA, Jin L, Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Van Kammen M, Levey AI, Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
   PubMed Web of Science ®Google Scholar
• Dunlop J, Beal McIlvain H, She Y, Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003;23:1688-96
   PubMed Web of Science ®Google Scholar
• Corona JC, Tovar-y-Romo LB, Tapia R. Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis. Expert Opin Ther Targets 2007;11:1415-28
   PubMed Web of Science ®Google Scholar
• Lanka V, Cudkowicz M. Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler 2008;9:131-40
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;(1):CD001447
   Google Scholar
• Andersen PM, Borasio GD, Dengler R, EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005;12(12):921-38
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218-26
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7
   PubMed Web of Science ®Google Scholar
• Vincent AM, Sakowski SA, Schuyler A, Strategic approaches to developing drug treatments for ALS. Drug Discov Today 2008;13:67-72
   PubMed Web of Science ®Google Scholar
• Sasaki S, Iwata M. Ultrastructural change of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Neurosci Lett 1999;268:29-32
   PubMed Web of Science ®Google Scholar
• Wong PC, Pardo CA, Borchelt DR, An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-16
   PubMed Web of Science ®Google Scholar
• Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann NY Acad Sci 2008;1147:37-52
   PubMed Web of Science ®Google Scholar
• Higgins CM, Jung C, Ding H, Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 2002;22:RC215, 1-6
   PubMed Web of Science ®Google Scholar
• Jaarsma D, Rognoni F, van Duijn W, CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol 2001;102:293-305
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-50
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I, A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-45
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, A clinical trial of creatine in ALS. Neurology 2004;63:1656-61
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6(12):1045-53
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709-20
   PubMed Web of Science ®Google Scholar
• Jindal DP, Chattopadhaya R, Guleria S, Synthesis and antineoplastic activity of 2-alkylaminoethyl derivatives of various steroidal oximes. Eur J Med Chem 2003;38:1025-34
   PubMed Web of Science ®Google Scholar
• Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol 2009;65(Suppl 1):S17-23
   Web of Science ®Google Scholar
• Traynor BJ, Bruijn L, Conwit R, Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20-7
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Katz J, Moore DH, Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:259-65
   PubMed Web of Science ®Google Scholar
• Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000;180:7-14
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Andersen PM, Nilsson P, Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999;8(2):157-64
   PubMed Web of Science ®Google Scholar
• Garcia ML, Singleton AB, Hernandez D, Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis. Neurobiol Dis 2006;21:102-9
   PubMed Web of Science ®Google Scholar
• Puls I, Oh SJ, Sumner CJ, Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005;57:687-94
   PubMed Web of Science ®Google Scholar
• Schmidt ER, Pasterkamp RJ, van den Berg LH. Axon guidance proteins: novel therapeutic targets for ALS? Prog Neurobiol 2009;88:286-301
   PubMed Web of Science ®Google Scholar
• Ruiz de Almodovar C, Lambrechts D, Mazzone M, Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009;89:607-48
   PubMed Web of Science ®Google Scholar
• He BP, Strong MJ. Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic. A comparative study of ALS and chronic aluminium chloride neurotoxicity in New Zealand white rabbits. Neuropathol Appl Neurobiol 2000;26:150-60
   PubMed Web of Science ®Google Scholar
• Miller R, Bradley W, Cudkowicz M. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-84
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Andres PL, Macdonald SA, Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009;10:99-106
   PubMed Web of Science ®Google Scholar
• Fornai F, Longone P, Cafaro L, Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-7
   PubMed Web of Science ®Google Scholar
• Chio A, Borghero G, Calvo A, Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010;75:619-25
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008;5:516-27
   PubMed Web of Science ®Google Scholar
• Giess R, Holtmann B, Braga M, Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet 2002;70:1277-86
   PubMed Web of Science ®Google Scholar
• Feldman EL, Sullivan KA, Kim B, Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis 1997;4:201-14
   PubMed Web of Science ®Google Scholar
• Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008;85:94-134
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Dewerchin M, Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92
   PubMed Web of Science ®Google Scholar
• Miller RG, Petajan JH, Bryan WW, A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996;39:256-60
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-9
   PubMed Web of Science ®Google Scholar
• Bongioanni P, Reali C, Sogos V, Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004;(3):CD004302
   Google Scholar
• Laaksovirtaa H, Soinila S, Hukkanen V, Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset. Eur J Neurol 2008;15:355-9
   PubMed Web of Science ®Google Scholar
• Aebischer P, Schluep M, Deglon N, Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2:696-9
   PubMed Web of Science ®Google Scholar
• Penn RD, Kroin JS, York MM, Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (Phase I trial). Neurosurgery 1997;40:94-9
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-30
   PubMed Web of Science ®Google Scholar
• Borasio GD, Robberecht W, Leigh PN, A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-6
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007;(4):CD002064
   Google Scholar
• Sorenson EJ, Windbank AJ, Mandrekar JN, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71:1770-5
   PubMed Web of Science ®Google Scholar
• Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:63-73
   PubMed Web of Science ®Google Scholar
• Nagano I, Shiote M, Murakami T. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 2005;27:768-72
   PubMed Web of Science ®Google Scholar
• Williams RM, McDonald A, O'Svage M, Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. Expert Opin Drug Metabol 2008;4:311-24
   PubMed Web of Science ®Google Scholar
• The BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (phase III). Neurology 1999;52(7):1427-33
   PubMed Web of Science ®Google Scholar
• Ochs G, Penn RD, York M, A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:201-6
   PubMed Web of Science ®Google Scholar
• Lunn JS, Hefferan MP, Marsala M, Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009;27:133-40
   PubMed Web of Science ®Google Scholar
• Robberecht W, Sapp P, Viaene MK, Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1994;62:384-7
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Warren L, Francis JW, Intrathecal administration of recombinant human superoxide disrnutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology 1997;49:213-22
   PubMed Web of Science ®Google Scholar
• Maxwell MM. RNAi applications in therapy development for neurodegenerative disease. Curr Pharm Des 2009;15:3977-91
   PubMed Web of Science ®Google Scholar
• Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005;6:24-35
   PubMed Web of Science ®Google Scholar
• Wroe R, Wai-Ling Butler A, Andersen PM, ALSOD: the amyotrophic lateral sclerosis. Online database. Amyotroph Lateral Scler 2008;9:249-50
   Google Scholar
• Grimm D, Streetz KL, Jopling CL, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441(7092):537-41
   PubMed Web of Science ®Google Scholar
• Jackson AL, Burchard J, Schelter J, Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-87
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-8
   PubMed Web of Science ®Google Scholar
• Wang H, Ghosh A, Baigude H, Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem 2008;283:15845-52
   PubMed Web of Science ®Google Scholar
• Locatelli F, Corti S, Papadimitriou D, Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann Neurol 2007;62:81-92
   PubMed Web of Science ®Google Scholar
• Ralph GS, Radcliffe PA, Day DM, Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11:429-33
   PubMed Web of Science ®Google Scholar
• Crooke ST. Antisense strategies. Curr Mol Med 2004;4:465-87
   PubMed Web of Science ®Google Scholar
• Smith RA, Miller TM, Yamanaka K, Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116:2290-6
   PubMed Web of Science ®Google Scholar
• Turner BJ, Cheah IK, Macfarlane KJ, Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem 2003;87:752-63
   PubMed Web of Science ®Google Scholar
• Spalloni A, Albo F, Ferrari F, Cu/Zn-superoxide dismutase (GLY933ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainite mediated toxicity in motor neurons in culture. Neurobiol Dis 2004;15:340-50
   PubMed Web of Science ®Google Scholar
• Rembach A, Turner BJ, Bruce S, Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J Neurosci Res 2004;77:573-82
   PubMed Web of Science ®Google Scholar
• Hedlund E, Hefferan MP, Marsala M, Cell therapy and stem cells in animal models of motor neuron disorders. Eur J Neurosci 2007;26:1721-37
   PubMed Web of Science ®Google Scholar
• Thonhoff JR, Ojeda L, Wu P. Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. Curr Stem Cell Res Ther 2009;4:178-99
   PubMed Web of Science ®Google Scholar
• Habisch HJ, Janowski M, Binder D, Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm 2007;114:1395-406
   PubMed Web of Science ®Google Scholar
• Chi L, Ke Y, Luo C, Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Stem Cells 2006;24:34-43
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321(5893):1218-21
   PubMed Web of Science ®Google Scholar
• Banfi A, Muraglia A, Dozin B, Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol 2000;28:707-15
   PubMed Web of Science ®Google Scholar
• Baxter MA, Wynn RF, Jowitt SN, Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004;22:675-82
   PubMed Web of Science ®Google Scholar
• Fattori E, Lazzaro D, Musiani P, IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci 1995;7:2441-9
   PubMed Web of Science ®Google Scholar
• Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500
   PubMedGoogle Scholar
• Ferrero I, Mazzini L, Rustichelli D, Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant 2008;17:255-66
   PubMed Web of Science ®Google Scholar
• Mazzini L, Fagioli F, Boccaletti R, Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:158-61
   PubMed Web of Science ®Google Scholar
• Deda H, Inci MC, Kurekci AE, Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derrived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18-25
   PubMed Web of Science ®Google Scholar
• Mazzini L, Ferrero I, Luparello V, Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol 2010;223:229-37
   PubMed Web of Science ®Google Scholar
• Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009;1:26-34
   Google Scholar
• Cashman N, Tan LY, Krieger C, Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 2008;37:620-5
   PubMed Web of Science ®Google Scholar
• Choi MR, Kim HJ, Park J-Y, Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010;472:94-8
   PubMed Web of Science ®Google Scholar
• Appel SH, Engelhardt JI, Henkel JS, Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008;71:1326-34
   PubMed Web of Science ®Google Scholar
• Zhao W, Xie W, Le W, Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol 2004;63:964-77
   PubMed Web of Science ®Google Scholar
• Zhao W, Xie W, Xiao Q, Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem 2006;99:1176-87
   PubMed Web of Science ®Google Scholar
• Mackenzie IR. The neuropathology of FTD associated With ALS. Alzheimer Dis Assoc Disord 2007;21(4):44-9
   Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG, Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61(5):427-34
   PubMed Web of Science ®Google Scholar
• Kuhnlein P, Sperfeld AD, Vanmassenhove B, Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol 2008;65:1185-9
   PubMedGoogle Scholar
• Vance C, Rogelj B, Hortobagyi T, Mutation in FUS, an RNA processing protein, cause familial amyotrophic Lateral sclerosis type 6. Science 2009;323:1208-11
   PubMed Web of Science ®Google Scholar
• Zhou H, Huang C, Chen H, Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet 2010;6(3):e1000887
   Web of Science ®Google Scholar
• Schmidt ER, Pasterkamp RJ, van den Berg LH. Axon guidance proteins: novel therapeutic targets for ALS? Prog Neurobiol 2009;88(4):286-301
   PubMed Web of Science ®Google Scholar
• Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2010;(6):CD005225
   Google Scholar
• Benatar M, Kurent J, Moore DH. Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2009;(1):CD006153
   Google Scholar
• Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2009;(4):CD004427
   PubMed Web of Science ®Google Scholar
• Ng L, Khan F, Mathers S. Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2009;(4):CD007425
   Google Scholar
• Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med 2008;5:e22
   PubMed Web of Science ®Google Scholar